Overview

Useful For
Identifying individuals with genetic variants in DPYD who are at increased risk of toxicity when prescribed 5-fluorouracil (5-FU) or capecitabine chemotherapy treatment

Genetics Test Information
This is a pharmacogenomics test associated with 5-fluorouracil and capecitabine drug sensitivity. Biallelic variation in the DPYD gene is also associated with dihydropyrimidine dehydrogenase (DPD) deficiency. Individuals who have variations identified in the DPYD may benefit from genetic consultation.

Special Instructions
• Informed Consent for Genetic Testing
• Pharmacogenomic Association Tables
• Multiple Genotype Test List
• Informed Consent for Genetic Testing (Spanish)

Method Name
Real-Time Polymerase Chain Reaction (PCR) with Allelic Discrimination Analysis

NY State Available
Yes

Specimen

Specimen Type
Varies

Ordering Guidance
This test does not detect or report variants other than the *2A, *7, *8, *10, *13, rs67376798, rs75017182, and rs115232898 alleles. Sequencing of the full gene is available for detection of additional variants as well as the alleles listed: order DPYDG / Dihydropyrimidine Dehydrogenase, DPYD Full Gene Sequencing, Varies.

Specimen Required
Multiple genotype tests can be performed on a single specimen after a single extraction. See Multiple Genotype Test List for a list of tests that can be ordered together.

Submit only 1 of the following specimens:

Specimen Type: Whole blood
Test Definition: DPYDQ
Dihydropyrimidine Dehydrogenase Genotype, Varies

Container/Tube: Lavender top (EDTA)
Specimen Volume: 3 mL
Collection Instructions:
1. Invert several times to mix blood.
2. Send whole blood specimen in original tube. Do not aliquot.
Specimen Stability Information: Ambient (preferred) 9 days/Refrigerated 30 days

Specimen Type: Saliva
Patient Preparation: Patient should not eat, drink, smoke, or chew gum 30 minutes prior to collection.
Supplies: Saliva Swab Collection Kit (T786)
Specimen Volume: 1 Swab
Collection Instructions: Collect and send specimen per kit instructions.
Specimen Stability Information: Ambient 30 days

Specimen Type: Extracted DNA
Container/Tube: 2-mL screw top tube
Specimen Volume: 100 mcL (microliters)
Collection Instructions:
1. The preferred volume is 100 mcL at a concentration of 50 ng/mcL.
2. Provide concentration of DNA and volume on tube.
Specimen Stability Information: Frozen (preferred)/Ambient/Refrigerated

Forms
1. New York Clients-Informed consent is required. Document on the request form or electronic order that a copy is on file. The following documents are available:
   - Informed Consent for Genetic Testing (T576)
   - Informed Consent for Genetic Testing (Spanish) (T826)
2. If not ordering electronically, complete, print, and send a Therapeutics Test Request (T831) with the specimen.

Specimen Minimum Volume
Blood: 0.4 mL
Saliva extracted DNA: see Specimen Required

Reject Due To

All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.

Specimen Stability Information

<table>
<thead>
<tr>
<th>Specimen Type</th>
<th>Temperature</th>
<th>Time</th>
<th>Special Container</th>
</tr>
</thead>
<tbody>
<tr>
<td>Varies</td>
<td>Varies</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Clinical & Interpretive
Clinical Information

5-Fluorouracil (5-FU) and its orally administered prodrug, capecitabine, are fluoropyrimidine-based chemotherapeutic agents that are widely used for the treatment of colorectal cancer and other solid tumors.

The dihydropyrimidine dehydrogenase (DPYD) gene encodes the rate-limiting enzyme for fluoropyrimidine catabolism and eliminates over 80% of administered 5-FU. Dihydropyrimidine dehydrogenase (DPYD) activity is subject to wide variability, mainly due to genetic variation. This results in a broad range of enzymatic deficiency from partial (3%-5% of population) to complete loss (0.2% of population) of enzyme activity. Patients who are deficient in DPYD are at an increased risk for side effects and toxicity when undergoing 5-FU treatment. In addition, pathogenic homozygous or compound heterozygous variants within DPYD are associated with dihydropyrimidine dehydrogenase (DPD) deficiency. DPD deficiency shows large phenotypic variability, ranging from no symptoms to a convulsive disorder with motor and intellectual disabilities.

The following table displays the DPYD variants detected by this assay, the corresponding star allele, and the effect on DPYD enzyme activity. Other or novel variations, besides those listed here, may also impact fluoropyrimidine-related side effects and tumor response.

<table>
<thead>
<tr>
<th>DPYD allele</th>
<th>cDNA nucleotide change</th>
<th>Effect on enzyme activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>*1</td>
<td>None (wild type)</td>
<td>Normal activity</td>
</tr>
<tr>
<td>*2A</td>
<td>1905+1G&gt;A</td>
<td>No activity</td>
</tr>
<tr>
<td>*7</td>
<td>299_302delTCAT</td>
<td>No activity</td>
</tr>
<tr>
<td>*8</td>
<td>703C&gt;T</td>
<td>No activity</td>
</tr>
<tr>
<td>*10</td>
<td>2983G&gt;T</td>
<td>No activity</td>
</tr>
<tr>
<td>*13</td>
<td>1679T&gt;G</td>
<td>No activity</td>
</tr>
<tr>
<td>rs67376798</td>
<td>2846A&gt;T</td>
<td>Decreased activity</td>
</tr>
<tr>
<td>rs75017182</td>
<td>1129-5923C&gt;G</td>
<td>Decreased activity</td>
</tr>
<tr>
<td>rs115232898</td>
<td>557A&gt;G</td>
<td>Decreased activity</td>
</tr>
</tbody>
</table>

Reference Values

An interpretive report will be provided.

Interpretation

An interpretive report will be provided.

For additional information regarding pharmacogenomic genes and their associated drugs, see Pharmacogenomic Associations Tables. This resource also includes information regarding enzyme inhibitors and inducers, as well as potential alternate drug choices.

Cautions

Rare genetic variants may be present that could lead to false-negative or false-positive results. Other variants in the primer binding regions can affect the testing, and ultimately, the genotype assessment made.

Samples may contain donor DNA if obtained from patients who received heterologous blood transfusions or allogeneic...
Dihydropyrimidine dehydrogenase (DPYD) genetic test results in patients who have undergone liver transplantation may not accurately reflect the patient's DPYD status.

Test results should be interpreted in the context of clinical findings, family history, and other laboratory data. Large deletions or rearrangements are not detected by this assay, and these may affect DPYD protein expression and their impact on fluoropyrimidine related side effects and tumor response.

This test is not designed to provide specific dosing or drug selection recommendations and is to be used as an aid to clinical decision making only. Drug-label guidance should be used when dosing patients with medications regardless of the predicted phenotype.

**Clinical Reference**


**Performance**

**Method Description**

Genomic DNA is extracted from whole blood or saliva. Genotyping for DPYD alleles is performed using a polymerase chain reaction (PCR)-based 5'-nuclease assay. Fluorescently labeled detection probes anneal to the target DNA. PCR is used to amplify the section of DNA that contains the variant. If the detection probe is an exact match to the target DNA, the 5'-nuclease polymerase degrades the probe, the reporter dye is released from the effects of the quencher dye, and a
fluorescent signal is detected. Genotypes are assigned based on the allele-specific fluorescent signals that are detected. (Unpublished Mayo method)

**PDF Report**
No

**Day(s) Performed**
Monday through Friday

**Report Available**
3 to 10 days

**Specimen Retention Time**
Whole blood/Saliva: 2 weeks; Extracted DNA: 2 months

**Performing Laboratory Location**
Rochester

**Fees & Codes**

**Fees**
- Authorized users can sign in to Test Prices for detailed fee information.
- Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact Customer Service.

**Test Classification**
This test was developed, and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.

**CPT Code Information**
81232

**LOINC® Information**

<table>
<thead>
<tr>
<th>Test ID</th>
<th>Test Order Name</th>
<th>Order LOINC® Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>DPYDQ</td>
<td>DPYD Genotype, V</td>
<td>93199-8</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Result ID</th>
<th>Test Result Name</th>
<th>Result LOINC® Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>610138</td>
<td>DPYD Phenotype</td>
<td>79719-1</td>
</tr>
<tr>
<td>610139</td>
<td>DPYD Activity Score</td>
<td>In Process</td>
</tr>
<tr>
<td>613999</td>
<td>DPYD Genotype</td>
<td>45284-7</td>
</tr>
<tr>
<td>610140</td>
<td>Interpretation</td>
<td>69047-9</td>
</tr>
<tr>
<td>610141</td>
<td>Additional Information</td>
<td>48767-8</td>
</tr>
<tr>
<td>Code</td>
<td>Type</td>
<td>Code</td>
</tr>
<tr>
<td>----------</td>
<td>-----------------</td>
<td>----------</td>
</tr>
<tr>
<td>610142</td>
<td>Method</td>
<td>85069-3</td>
</tr>
<tr>
<td>610143</td>
<td>Disclaimer</td>
<td>62364-5</td>
</tr>
<tr>
<td>610144</td>
<td>Reviewed by</td>
<td>18771-6</td>
</tr>
</tbody>
</table>